Source: GW Pharmaceuticals.
Whether you’re ready to admit it or not, the marijuana movement may be unstoppable.
As Gallup reported in October of last year, for the first time in history, more respondents were in favor of legalizing marijuana than were opposed to its legalization. To put this into some context, just 34% of respondents were in favor of legalization in 2004, demonstrating just how swiftly the tide has turned in favor of legalization.
Marijuana’s medical benefits take stage
But, the legal marijuana movement may yet gain even more steam on the heels of its possible medical benefits. GW Pharmaceuticals (NASDAQ: GWPH ) has devoted its pipeline to discovering cannabinoids from the cannabis plant it plans to use to effect biologic change via the natural cannabinoid receptor system discovered by GW within our bodies. GW Pharmaceuticals already has Sativex approved in more than a dozen countries outside the United States to treat spasticity associated with multiple sclerosis and has the hope of bringing its cannabinoid-based drug to U.S. pharmacy shelves soon, depending on the results from its three late-stage clinical studies examining Sativex as a treatment for cancer pain.
GW Pharmaceuticals isn’t alone, either. Insys Therapeutics (NASDAQ: INSY ) is in the process of developing a longer-lasting version of THC-based Marinol which it hopes can be used to prevent nausea in patients who are undergoing chemotherapy.
Source; GW Pharmaceuticals.
Furthermore, additional studies have emerged that hint at medical marijuana’s benefits over traditional medicines. As we examined in late August based on an abstract published by JAMA Internal Medicine, medical marijuana may also be a smart solution to lowering long-term medical care costs due to its ability to divert chronic pain sufferers from using and …read more